Hideki Kawai

Dr. Hideki Kawai

orcid

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 June 2020 in ESC Heart Failure
Verified
Journal Article
Open access
PDF file
HKHideki Kawai
Hideki Kawai
MSMasayoshi Sarai
Masayoshi Sarai
YKYasuchika Kato
Yasuchika Kato
HNHiroyuki Naruse
Hiroyuki Naruse
AWAyumi Watanabe
Ayumi Watanabe
YOYukio Ozaki
Yukio Ozaki
Aims In the updated guidelines for cardiac sarcoidosis (CS) proposed by the Japanese Circulation Society (JCS), the definition of isolated CS (iCS) was established for the first time. This prompted us to examine the characteristics of patients with CS including iCS according to them by reviewing patients undergoing 18F‐fluoro‐2‐deoxyglucose positron‐emission tomography/computerized tomography (FDG‐PET/CT), compared with those with CS determined by the conventional international criteria. Methods and results From 2013 to 2019, 94 patients (61 ± 15 years, 50 female patients) with suspected CS underwent whole‐body and cardiac FDG‐PET/CT scanning. In contrast to 22 patients with CS based on the international criteria, 34 [27 with systemic sarcoidosis including cardiac involvement (sCS) and 7 with definitive iCS] were diagnosed with CS according to the new JCS guidelines (P = 0.012), and 60 were not (4 suspected iCS, 13 systematic sarcoidosis without cardiac involvement, and 43 no sarcoidosis). In addition to 26 of 34 patients with CS, corticosteroids were also started in 6 of 60 without CS according to clinical need. Conclusions Diagnostic yield with the new JCS guidelines was higher, with approximately 1.5‐fold of the patients diagnosed with CS compared with the previous international criteria and definitive iCS accounting for approximately 20% of the whole CS cohort. In addition to 75% of the patients with sCS or definitive iCS in the updated guidelines, 10% in whom CS was not documented were also started on corticosteroids for clinical indications such as reduced cardiac function or arrhythmia.

6 September 2023 in European Radiology
Verified
Journal Article
Closed access
PDF file
HKHideki Kawai
Hideki Kawai
SMSadako Motoyama
Sadako Motoyama
MSMasayoshi Sarai
Masayoshi Sarai
YSYoshihiro Sato
Yoshihiro Sato
TMTakahiro Matsuyama
Takahiro Matsuyama
HIHideo Izawa
Hideo Izawa


1 March 2015 in Journal of Cardiology
Verified
Journal Article
Closed access
HKHideki Kawai
Hideki Kawai
EWEiichi Watanabe
Eiichi Watanabe
MYMayumi Yamamoto
Mayumi Yamamoto
HHHiroto Harigaya
Hiroto Harigaya
KSKan Sano
Kan Sano
YOYukio Ozaki
Yukio Ozaki

2 July 2014 in Heart and Vessels
Verified
Journal Article
Closed access
PDF file
HKHideki Kawai
Hideki Kawai
YTYoko Takakuwa
Yoko Takakuwa
HNHiroyuki Naruse
Hiroyuki Naruse
MSMasayoshi Sarai
Masayoshi Sarai
SMSadako Motoyama
Sadako Motoyama
YOYukio Ozaki
Yukio Ozaki

10 February 2020 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
HNHiroyuki Naruse
Hiroyuki Naruse
JIJunnichi Ishii
Junnichi Ishii
HTHiroshi Takahashi
Hiroshi Takahashi
FKFumihiko Kitagawa
Fumihiko Kitagawa
HNHideto Nishimura
Hideto Nishimura
YOYukio Ozaki
Yukio Ozaki
We prospectively investigated the prognostic value of urinary liver-type fatty-acid-binding protein (L-FABP) levels on hospital admission, both independently and in combination with serum creatinine-defined acute kidney injury (AKI), to predict long-term adverse outcomes in 1119 heterogeneous patients (mean age; 68 years) treated at medical (non-surgical) cardiac intensive care units (CICUs). Patients with stage 5 chronic kidney disease were excluded from the study. Of these patients, 47% had acute coronary syndrome and 38% had acute decompensated heart failure. The creatinine-defined AKI was diagnosed according to the “Kidney Disease: Improving Global Outcomes” criteria. The primary endpoint was a composite of all-cause death or progression to end-stage kidney disease, indicating the initiation of maintenance dialysis therapy or kidney transplantation. Creatinine-defined AKI occurred in 207 patients, with 44 patients having stage 2 or 3 disease. During a mean follow-up period of 41 months after enrollment, the primary endpoint occurred in 242 patients. Multivariate Cox regression analyses revealed L-FABP levels as independent predictors of the primary endpoint (p < 0.001). Adding L-FABP to a baseline model with established risk factors further enhanced reclassification and discrimination beyond that of the baseline model alone, for primary-endpoint prediction (both; p < 0.01). On Kaplan–Meier analyses, increased L-FABP (≥4th quintile value of 9.0 ng/mL) on admission or presence of creatinine-defined AKI, correlated with an increased risk of the primary endpoint (p < 0.001). Thus, urinary L-FABP levels on admission are potent and independent predictors of long-term adverse outcomes, and they might improve the long-term risk stratification of patients admitted at medical CICUs, when used in combination with creatinine-defined AKI.